Remove Hospital Remove Medical Remove Therapy
article thumbnail

Study Explores Virus-based Therapy for Neoadjuvant Treatment of BCC

The Dermatology Digest

All treated tumours at least became smaller, and no tumour grew further under the therapy. The treatment was well tolerated by the patients,” says the principal investigator Christoph Hller, Head of the Skin Tumour Centre at the Department of Dermatology at the Medical University of Vienna in Vienna, Austria, in a news release.

Therapy 67
article thumbnail

2025 travel & wellness trends according to the experts

Spa Executive

We asked global wellness and hospitality experts this question: What trends do you see emerging in wellness and travel for 2025, and how can hotels and spas prepare and adapt? Here’s what our experts had to say about the ways hospitality businesses are reshaping their approaches to meet the evolving expectations of today’s traveler in 2025.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Maui Derm News: DecisionDx-SCC Improves Risk Stratification Among Patients With SCC Tumors on the Head or Neck When Combined With BWH Staging

The Dermatology Digest

.’s DecisionDx-SCC test improves risk stratification of patients with cutaneous squamous cell carcinoma (SCC) tumors located on the head or neck when the tests results are combined with Brigham and Womens Hospital (BWH) staging, new research shows.

article thumbnail

Torqur AG’s Bimiralisib Gel Shows Promise in AK

The Dermatology Digest

Dr. David Fisher, Chair of the Dermatology Department at Massachusetts General Hospital (MGH) and Harvard Medical School in Boston, MA, in a news release. Alexander Navarini, lead Principal Investigator and Chairman of the Department of Dermatology and Allergy at the University Hospital Basel in Switzerland.

article thumbnail

Dupilumab (Dupixent, Sanofi & Regeneron) Shows More Promise in BP

The Dermatology Digest

Sustained disease remission was defined as complete clinical remission with completion of OCS taper by week 16 without relapse and no rescue therapy use during the 36-week treatment period. 1678mg reduction in cumulative OCS exposure on average and a 54% lower risk of rescue medication use.

article thumbnail

Meet the First-ever Recipients of The Lupus Research Alliance’s Translational Bridge Award

The Dermatology Digest

” The TBA recipients include: Innovating Pain and Fatigue Management Cynthia Aranow, MD, The Feinstein Institutes for Medical Research Dr. Aranow will evaluate the use of a new, non-toxic, non-painful device that stimulates the vagus nerve to reduce pain and fatigue in people with SLE.

article thumbnail

Driving hospitality revenue with innovative sleep tourism programs

Spa Executive

These programs, which vary across locations, incorporate yoga nidra and meditation, relaxing treatments and amenities, wellness therapies, nutrition advice and low intensity training. The post Driving hospitality revenue with innovative sleep tourism programs appeared first on Spa Executive. Learn more at book4time.com.